IDH1 and central nervous system cancer: Niraparib (NCT05076513) is being evaluated in recurrent IDH-mutant glioma (cohort B) study, while many combinational drugs like pamiparib/TMZ (NCT03914742) and radiotherapy along with carboplatin/talazoparib (NCT04740190) are studied in high-grade glioma with PTEN-mutant, IDH-mutant, and BRCAness signatures (Sim et al., 2022).